Abstract:Alzheimer's disease (AD) is a progressive neurological disorder that affects the central nervous system (CNS), leading to memory and cognitive decline. In AD, the brain experiences three main structural changes: a significant decrease in the quantity of neurons, the development of neurofibrillary tangles (NFT) composed of hyperphosphorylated tau protein, and the formation of amyloid beta (Aβ) or senile plaques, which are protein deposits found outside cells and surrounded by dystrophic neurites. Genetic studies have identified four genes associated with autosomal dominant or familial early-onset AD (FAD): amyloid precursor protein (APP), presenilin 1 (PS1), presenilin 2 (PS2), and apolipoprotein E (ApoE). The formation of plaques primarily involves the accumulation of Aβ, which can be influenced by mutations in APP, PS1, PS2, or ApoE genes. Mutations in the APP and presenilin (PS) proteins can cause an increased amyloid β peptides production, especially the further form of amyloidogenic known as Aβ42. Apart from genetic factors, environmental factors such as cytokines and neurotoxins may also have a significant impact on the development and progression of AD by influencing the formation of amyloid plaques and intracellular tangles. Exploring the causes and implications of protein aggregation in the brain could lead to innovative therapeutic approaches. Some promising therapy strategies that have reached the clinical stage include using acetylcholinesterase inhibitors, estrogen, nonsteroidal anti-inflammatory drugs (NSAIDs), antioxidants, and antiapoptotic agents. The most hopeful therapeutic strategies involve inhibiting activity of secretase and preventing the β-amyloid oligomers and fibrils formation, which are associated with the β-amyloid fibrils accumulation in AD. Additionally, immunotherapy development holds promise as a progressive therapeutic approach for treatment of AD. Recently, the two primary categories of brain stimulation techniques that have been studied for the treatment of AD are invasive brain stimulation (IBS) and non-invasive brain stimulation (NIBS). In this article, the amyloid proteins that play a significant role in the AD formation, the mechanism of disease formation as well as new drugs utilized to treat of AD will be reviewed.

[Disease-modifying Drugs for non-Alzheimer Dementias]

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

[Anti-amyloid Antibody Drugs as Disease-Modifying Therapies for Alzheimer's Disease]

Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets

Protein aggregation and its affecting mechanisms in neurodegenerative diseases

TDP-43 as a therapeutic target in neurodegenerative diseases: Focusing on motor neuron disease and frontotemporal dementia

Alzheimer's disease: The role of proteins in formation, mechanisms, and new therapeutic approaches

The Search for a Universal Treatment for Defined and Mixed Pathology Neurodegenerative Diseases

Neuroimmune Dysfunction in Alzheimer's Disease and Other Forms of Dementia

Novel Disease-Modifying Therapies for Alzheimer's Disease.

The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention

Co-Aggregation of TDP-43 with Other Pathogenic Proteins and Their Co-Pathologies in Neurodegenerative Diseases

Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer's Disease

Recent Progress In The Drug Development For The Treatment Of Alzheimer'S Disease Especially On Inhibition Of Amyloid-Peptide Aggregation

Development of small molecules for disrupting pathological amyloid aggregation in neurodegenerative diseases

Molecular Therapeutics in Development to Treat Alzheimer's Disease

Development of disease‐modifying therapies against Alzheimer's disease

Small-Molecule Amyloid Beta-Aggregation Inhibitors in Alzheimer's Disease Drug Development

Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules

In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use

Indole-3-acetic Acid, a Potential Therapeutic Target in Alzheimer's Disease.